Loading
Sapu Nano
Sapu Nano reformulates existing cancer drugs as extremely small particles that can be given into a vein. Its first product, Sapu003, is an intravenous form of the mTOR inhibitor everolimus, in an early trial in several advanced solid tumours.
Also called: SAPU NANO (US) LLC
Overview
Sapu Nano is a San Diego nanomedicine company whose Deciparticle platform formulates water-insoluble drugs as nanoparticles smaller than 20 nm for intravenous use; its manufacturing is done at the Sapu Bioscience GMP facility in San Diego. The website links the platform's lineage to Vuong Trieu, co-inventor of Abraxane, and a survey paper on the platform was released by Oncotelic. Its lead product Sapu003 (SAPU-003) is a weekly intravenous Deciparticle formulation of everolimus; the company says it gives full systemic exposure to both mTOR complexes and reduces gut accumulation compared with oral everolimus. The first patient was dosed in May 2026. Its first registered cancer trial, NCT07369505, a phase 1b dose-escalation study of Sapu003 alone or with exemestane in advanced mTOR-sensitive solid tumours (HR-positive, HER2-negative breast cancer, renal cell carcinoma, neuroendocrine tumours, tuberous sclerosis complex-associated tumours and hepatocellular carcinoma) in Adelaide, Australia, was posted on ClinicalTrials.gov in January 2026.
Notes
- Founding year, ownership and financing are not stated on the company website. The relationship between Sapu Nano, Sapu Bioscience and Oncotelic is not set out on the pages read; the news page calls Sapu Nano a subsidiary without naming the parent.
- The company's claims of 100% bioavailability and reduced toxicity are its own and come from preclinical and pharmacokinetic data; no clinical efficacy has been reported.
- OnCo has no technology record for nanoparticle drug reformulation; the record is linked to PI3K, AKT and mTOR inhibitors because everolimus inhibits mTOR.
- Company website read on 29 October 2026.
Connected
7Similar pages
- CompanyTorqur
Shares mTOR, PI3K, AKT and mTOR inhibitors.
- TargetFKBP12 (FKBP1A)
Shares mTOR, Renal cell carcinoma, HR-positive / HER2-negative breast cancer.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Shares PI3K, AKT and mTOR inhibitors, HR-positive / HER2-negative breast cancer.
- TreatmentSapanisertib
- CompanyKymaThera
Shares PI3K, AKT and mTOR inhibitors, HR-positive / HER2-negative breast cancer.
- TrialStudy to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
Shares PI3K, AKT and mTOR inhibitors, HR-positive / HER2-negative breast cancer.
- TrialRADIANT-3 and RADIANT-4
Shares PI3K, AKT and mTOR inhibitors, Neuroendocrine tumours.
- TrialA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Shares PI3K, AKT and mTOR inhibitors, HR-positive / HER2-negative breast cancer.
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
sapunano.com · 3
A source that has moved or gone is reported by the weekly link check. /audit/